Mucormycosis, past and present : a comprehensive review
Mucormycosis is an emerging opportunistic angioinvasive fungal infection. Predisposing factors such as diabetes, neutropenia, long-term corticosteroid therapy, solid organ transplantation and immunosuppression contribute to its occurrence. This disease was not of significant concern prior to the COVID-19 pandemic, but gained prominence due to infections in COVID-19 patients. Mucormycosis needs special attention and coordinated efforts of the scientific community and medical professionals to reduce morbidity and mortality. Here we present an overview of the epidemiology and prevalence of mucormycosis in the pre- and post-COVID-19 eras, the factors that contributed to the abrupt increase in COVID-19-associated mucormycosis (CAM), the actions taken by the regulatory agencies (including Code Mucor and CAM registry), the existing diagnostic tools and CAM management strategies.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:18 |
|---|---|
| Enthalten in: |
Future microbiology - 18(2023) vom: 27. Feb., Seite 217-234 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Gupta, Ishita [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Angioinvasion |
|---|
| Anmerkungen: |
Date Completed 05.04.2023 Date Revised 11.04.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.2217/fmb-2022-0141 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM354760394 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM354760394 | ||
| 003 | DE-627 | ||
| 005 | 20231226062917.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2217/fmb-2022-0141 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1182.xml |
| 035 | |a (DE-627)NLM354760394 | ||
| 035 | |a (NLM)36970978 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Gupta, Ishita |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Mucormycosis, past and present |b a comprehensive review |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 05.04.2023 | ||
| 500 | |a Date Revised 11.04.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Mucormycosis is an emerging opportunistic angioinvasive fungal infection. Predisposing factors such as diabetes, neutropenia, long-term corticosteroid therapy, solid organ transplantation and immunosuppression contribute to its occurrence. This disease was not of significant concern prior to the COVID-19 pandemic, but gained prominence due to infections in COVID-19 patients. Mucormycosis needs special attention and coordinated efforts of the scientific community and medical professionals to reduce morbidity and mortality. Here we present an overview of the epidemiology and prevalence of mucormycosis in the pre- and post-COVID-19 eras, the factors that contributed to the abrupt increase in COVID-19-associated mucormycosis (CAM), the actions taken by the regulatory agencies (including Code Mucor and CAM registry), the existing diagnostic tools and CAM management strategies | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a CAM | |
| 650 | 4 | |a COVID-19-associated mucormycosis | |
| 650 | 4 | |a angioinvasion | |
| 650 | 4 | |a black fungus | |
| 650 | 4 | |a diagnosis | |
| 650 | 4 | |a epidemiology | |
| 650 | 4 | |a invasive fungal disease | |
| 650 | 4 | |a mucormycosis | |
| 650 | 4 | |a pathogenesis | |
| 650 | 4 | |a post-COVID-19 complications | |
| 650 | 4 | |a treatment | |
| 700 | 1 | |a Baranwal, Pritika |e verfasserin |4 aut | |
| 700 | 1 | |a Singh, Gagandeep |e verfasserin |4 aut | |
| 700 | 1 | |a Gupta, Vandana |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Future microbiology |d 2006 |g 18(2023) vom: 27. Feb., Seite 217-234 |w (DE-627)NLM171766504 |x 1746-0921 |7 nnns |
| 773 | 1 | 8 | |g volume:18 |g year:2023 |g day:27 |g month:02 |g pages:217-234 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2217/fmb-2022-0141 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 18 |j 2023 |b 27 |c 02 |h 217-234 | ||